Investigators from the Cleveland Clinic Cole Eye Institute, Cleveland, reported the results of a study that identified macular structural and vascularity changes in adults who had been born ...
A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need ...
The 1-year results from the HELIOS Trial that evaluated the investigational intravitreal Axitinib implant (OTX-TKI, Ocular Therapeutix) for the treatment of non-proliferative diabetic retinopathy ...
Panelists discuss how patients experiencing frequent anti-VEGF treatment burdens with 4- to 8-week intervals between injections are ideal candidates for PDS as an alternative delivery method.
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa. Clinical stage biopharmaceutical company Nacuity ...
Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard ...
A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.
Hello and welcome to this video series sponsored by Bayer in which we are going to explore Eylea 8 mg for the treatment of age-related macular degeneration and diabetic macular edema. I am Professor ...